Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 96

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 4
Chunk 96
---
 2024, we had 1,260 scientists and support staff dedicated to research and development.
We have several decades of successful innovation history. For example, we developed a unique fractionation design that reduces the risk of contamination and maintenance costs and increases the amount of product extracted per liter of plasma. We also developed the first centrifugation unit for the automated cleaning of blood cells. In addition, we were one of the first plasma fractionators to conduct double viral inactivation processes for Factor VIII and have designed and implemented a new process for the sterile filling of vials that reduces exposure to potential contaminants as compared to other existing processes. Further, we have developed a nanofiltration method of viral inactivation for our IG, alpha-1 PI, and ATIII products.
Our key therapeutic areas of study focus on immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. Our next innovations into these therapeutic areas will go beyond plasma-derived proteins, as our significant investments to increase R&D capabilities are allowing us to develop a new class of recombinant antibodies and small-molecules candidates.
Biopharma Initiatives
We have a number of research and development projects in our Biopharma business unit underway, 15 of which are in the clinical development phase. The following table reflects the total number of research and development projects in our Biopharma business unit by development phase as of the end of the last three years.

                        ​                           ​     ​     ​     ​     ​     ​ 
------------------------------------------------------------------------------------
​                                                    ​            As of December 31,
Development Phase                                       2024        2023        2022
Discovery                                                 19          24          19
Pre-clinical                                              32          23          28
Clinical                                                  15          22          23
Post Commercialization Studies                             6          14          39
Rest of projects                                          10          16          14
Total Biopharma Research and Development Projects         82          99         123
​
​

62

The table below presents the most important of our research and development projects:
​

Product Candidate                  Therapeutic               Product              Potential Use                                                                                             Development Phase                                                                                                                                                                        
                                   Area                      Type                                                                                                                                                                                                                                                                                                                    
​                              ​   ​                     ​   ​                ​   ​                                                                                                     ​   ​                                                                                                                                                                                        
Xembify®                           Immunology                Plasma-derived       Secondary Immunodeficiency in Chronic Lymphotic Leukemia, Multiple Myeloma